Vigil NeuroscienceVIGL
VIGL
About: Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
Employees: 67
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
16% more capital invested
Capital invested by funds: $38.4M [Q4 2024] → $44.5M (+$6.11M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
1.69% less ownership
Funds ownership: 55.32% [Q4 2024] → 53.63% (-1.69%) [Q1 2025]
2% less funds holding
Funds holding: 51 [Q4 2024] → 50 (-1) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
2%
upside
Avg. target
$8
2%
upside
High target
$8
2%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Stifel Paul Matteis | 2%upside $8 | Hold Downgraded | 28 May 2025 |
HC Wainwright & Co. Andrew Fein | 2%upside $8 | Neutral Downgraded | 27 May 2025 |
Wedbush Laura Chico | 2%upside $8 | Neutral Downgraded | 22 May 2025 |
Financial journalist opinion
Based on 15 articles about VIGL published over the past 30 days
Neutral
PRNewsWire
5 days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal rights and options . Vigil Neuroscience, Inc. (NASDAQ: VIGL)'s sale to Sanofi.
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
1 week ago
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm
PHILADELPHIA , June 4, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil Neuroscience, Inc. ("Vigil") (NASDAQ: VIGL) shareholders. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/vigil-neuroscience/ On May 21, 2025, Vigil announced that it had agreed to be acquired by Sanofi at an upfront price of $8.00 per share in cash plus a non-transferable contingent value right (CVR) worth an additional $2.00 in cash upon the achievement of certain milestones.
Neutral
GlobeNewsWire
1 week ago
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Positive
Zacks Investment Research
1 week ago
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Neutral
GlobeNewsWire
3 weeks ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL ), relating to the proposed merger with French company, Sanofi. Under the terms of the agreement, Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. Click here for more https://monteverdelaw.com/case/vigil-neuroscience-inc-vigl/. It is free and there is no cost or obligation to you.
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
3 weeks ago
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an ad.
Neutral
Investors Business Daily
3 weeks ago
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.
Neutral
Business Wire
3 weeks ago
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Vigil will receive $8.00 per share of common stock in cash. Vigil shareholders will also recei.
Charts implemented using Lightweight Charts™